| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02895945 2015-005521-39 Details | 2021-10-20 Interventional | 3 | 8 | Factor VIII Hemophilia A | Takeda has determined that the benefit/risk profile does not support continuation of the
surgery Study for this specific Congenital Hemophilia A with Inhibitors patient population. Study was discontinued as Takeda determined that the benefit/risk profile did not support continuation of the surgery study for this specific Congenital Hemophilia A with Inhibitors participant population. | |||
| NCT01111539 2010-018796-21 Details | 2021-10-20 Interventional | 3 | 211 | Aripiprazole Escitalopram Depression Depressive Diso… Depressive Diso… Major Depressiv… | The study was terminated early due to Sponsor decision, closure of this combination therapy
program is unrelated to any safety issues, no signals of concern. The trial was terminated to allow support of additional programs in the central nervous system (CNS) therapeutic area where limited therapies are available and, thus, there exists heightened unmet medical need and is unrelated to any safety issues. | |||
| NCT00633958 Details | 2021-10-20 Interventional | 1 | 2 | Alovudine Central Nervous… Tumors of the C… | Large phase II opened to accue same patients - | |||
| NCT05084456 Details | 2021-10-19 Interventional | 1 | 0 | Docetaxel Liver Diseases Impaired Liver … Solid Tumor, Ad… | Pending further development - | |||
| NCT01587144 Details | 2021-10-19 Interventional | 2 | 18 | Lucanthone Temozolomide Glioblastoma Glioblastoma Mu… | Sponsor's decision - | |||
| NCT03655080 Details | 2021-10-18 Interventional | 2 | 2 | Albumin-Bound P… Paclitaxel Spinal Cord Com… Cord Compressio… | Pharmaceutical company decided to close study - | |||
| NCT02740114 Details | 2021-10-18 Interventional | 3 | 105 | Bupivacaine Oxycodone Genital Neoplas… Neoplasms Gynecologic Can… Malignant Neopl… | Per PIs request - | |||
| NCT00256776 2005-001628-35 Details | 2021-10-18 Interventional | 3 | 269 | Bortezomib Dexamethasone Thalidomide Multiple Myelom… Neoplasms, Plas… | - - | |||
| NCT04052204 2019-001358-24 Details | 2021-10-14 Interventional | 1/2 | 3 | Avelumab Talazoparib Squamous Cell C… Metastatic Cast… Squamous Cell C… | Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not
provide additional clinical benefit over current or future Standard of Care in the different
therapeutic indications that this trial was to evaluate. Phase 1b part of Combination A was conducted but not completed as company terminated this study on 21 May 2021. Termination was not due to a regulatory request or new emerging safety signals. Test for Combination B, Combination C and Phase 2 expansion for Combination A planned in the protocol were not conducted. | |||
| NCT03199755 Details | 2021-10-14 Interventional | 2 | 0 | Artemether Artemether, Lum… Lumefantrine Malaria | Withdrawn in 2018 because clinicians did not follow protocols, issues with communication and
also with tablet processing, nearby Ebola outbreak in 2018 (in the N Kivu area) confounded
efforts. - | |||
| NCT03838692 Details | 2021-10-13 Interventional | 2 | 0 | Ponatinib Carcinoma, Neur… Thyroid Disease… Thyroid Neoplas… Medullary Thyro… | Closed by sponsor - | |||
| NCT03353259 2017-001670-42 Details | 2021-10-13 Interventional | 2/3 | 382 | Tranexamic Acid Hematoma Hematoma, Subdu… Hematoma, Subdu… Chronic Subdura… | DMC concluded that the results of 382 included patients were clear. - | |||
| NCT02213042 2014-001220-30 Details | 2021-10-13 Interventional | 2 | 42 | Aromatase Inhib… Lapatinib Trastuzumab Breast Neoplasm… Neoplasms, Brea… | Primary analysis was completed in 2018 and continued minimal data collection from the one
participant active in the study was not expected to add meaningful knowledge to the
understanding of lapatinib - | |||
| NCT01773785 Details | 2021-10-13 Interventional | 2 | 30 | Docetaxel Biliary Tract N… Biliary Cancer | The study completed the first phase and did not meet efficacy end point to enter into the
randomized phase. - | |||
| NCT01741155 Details | 2021-10-13 Interventional | 2 | 34 | Docetaxel Carcinoma, Non-… Lung Neoplasms Non Small Cell … | The study did not meet efficacy end point and did not enroll patients in the randomized phase. - | |||
| NCT04431466 Details | 2021-10-12 Interventional | 2 | 32 | Ivermectin Coronavirus Inf… Infections Coronavirus Inf… | Preliminary data from a pilot study suggest that the administration of ivermectin in patients
with SARS-CoV-2 is safe, reducing symptoms and viral load. The antiviral effects of ivermectin
appear to depend on the dose administered. - | |||
| NCT03176264 2017-000520-96 Details | 2021-10-12 Interventional | 1 | 1 | Bevacizumab Spartalizumab Colorectal Neop… Metastatic Colo… | The study was terminated early due to company decision. - | |||
| NCT02387216 Details | 2021-10-12 Interventional | 2 | 153 | Docetaxel Carcinoma, Non-… Lung Neoplasms Adenocarcinoma Heregulin NSCLC Non-Small Cell … | Based on the preliminary results seen during interim analysis, which were confirmed in the
final analysis, the Sponsor terminated the study - | |||
| NCT01379469 Details | 2021-10-12 Interventional | 2 | 20 | Carbamazepine Alpha 1-Antitry… Liver Cirrhosis Liver Diseases Alpha-1-antitry… | - The primary & secondary outcomes could not be assessed because the number of subjects with available pre & post biopsies was insufficient in subject number and sample quality to conduct the analyses. As described in more detail in Outcome Measures. . | |||
| NCT03629249 2018-000212-25 Details | 2021-10-11 Interventional | 3 | 604 | Indoleacetic Ac… Asthma | Company decision - |